Key result
Efonidipine preserved renal function and significantly reduced arterial stiffness and oxidative stress compared to amlodipine over 12 months in type 2 diabetic patients with hypertension and nephropathy.
Why the study?
Does efonidipine improve renal function and arterial stiffness compared to amlodipine in type 2 diabetic patients with hypertension and nephropathy?
RCT (n=40)
Open-label
Randomized
No
Does efonidipine improve renal function and arterial stiffness compared to amlodipine in type 2 diabetic patients with hypertension and nephropathy?
In type 2 diabetic patients with hypertension and nephropathy, efonidipine (a T- and L-type CCB) preserved renal function and reduced arterial stiffness compared to amlodipine, potentially due to its oxidative stress-reducing and aldosterone-lowering effects.
Answers are grounded in this paper and cite their sources.
Efonidipine may be preferred over amlodipine in diabetic hypertensive nephropathy; extends randomized CCB comparisons with renal and stiffness endpoints.
AIM: The three types of calcium channel blocker (CCB), L-, T- and N-type, possess heterogeneous actions on endothelial function and renal microvascular function. In the present study, we evaluated the effects of two CCBs, efonidipine and amlodipine, on renal function and arterial stiffness. METHODS: Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months. Arterial stiffness was evaluated by the cardio-ankle vascular index (CAVI). RESULTS: Changes in blood pressure during the study were almost the same in the two groups. Sig-nificant increases in serum creatinine and urinary albumin and a significant decrease in the esti-mated glomerular filtration rate were observed in the amlodipine group, but not in the efonidipine group. On the other hand, significant decreases in plasma aldosterone, urinary 8-hydroxy-2'-deoxy-guanosine and CAVI were observed after 12 months in the efonidipine group, but not in the amlo-dipine group. CONCLUSIONS: These results suggest that efonidipine, which is both a T-type and L-type calcium chan-nel blocker, has more favorable effects on renal function, oxidative stress and arterial stiffness than amlodipine, an L-type calcium channel blocker.
No takes yet. Share an insight, caveat, or question.
Sasaki et al. (2009) conducted an RCT in Type 2 diabetes with hypertension and nephropathy (n=40). Efonidipine vs. Amlodipine 5 mg/day was evaluated on Renal function (serum creatinine, urinary albumin, eGFR) and arterial stiffness (CAVI). Efonidipine preserved renal function and significantly reduced arterial stiffness and oxidative stress compared to amlodipine over 12 months in type 2 diabetic patients with hypertension and nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: